ClinicalTrials.gg
RecruitingNCT06954831Updated Oct 30, 2026

Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer

A Phase 2 interventional study of Cone-Beam Computed Tomography and Hypofractionated External Beam Radiation Therapy in Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 and Anatomic Stage III Breast Cancer AJCC v8, sponsored by City of Hope Medical Center. Recruiting at 7 sites in United States. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by City of Hope Medical Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
40 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Breast Neoplasms by City of Hope Medical Center — 17 open to participants now, 39 under way, 1 of them phase 3. Breast Neoplasms · City of Hope Medical Center.

Planned enrollment
13th of 76
82 · median 36
Started
2025
with 5 others
Phase 2
25 of 89
7 open now
Primary completion
2028-01
later than 29 of 38 live
Registered
85th of 89
by date

Among the 89 studies in Breast Neoplasms by City of Hope Medical Center, this one is the 13th largest by planned enrollment of the 76 interventional ones that give a count, is one of 6 that started in 2025, is one of 25 in phase 2, reaches primary completion later than 29 of the 38 other live ones, and was the 85th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 89 studies in Breast Neoplasms by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Breast Neoplasms by City of Hope Medical Center, or all of them as a file.
02

Study summary

This clinical trial tests how well ultra-hypofractionated (UF) whole breast irradiation (WBI) with lumpectomy cavity boost (CB) works in treating patients with stage I-III breast cancer. Breast conservation therapy (BCT) is the recommended treatment for patients with early stage breast cancer. BCT involves a lumpectomy followed by breast radiation. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Traditionally, WBI has been given once daily over 5-6 weeks and then those at high-risk for recurrence receive additional radiation (boost) to the lumpectomy cavity daily over 4-8 days. This has now been replaced by moderate hypofractionated radiation. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Although moderate hypofractionated radiation therapy reduces the length of treatment from 6-7 weeks to 3-4 weeks, the length of treatment still remains a barrier for many patients. UF-WBI with CB delivers radiation to the whole breast and the surgical cavity at the same time over 5 daily treatments. Giving UF-WBI with CB may prevent recurrence and prolong survival as well as improve the quality of life in patients with stage I-III breast cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the impact of UF-WBI + CB as assessed by patient-reported Global Cosmesis Score (GCS) at 1 year.

SECONDARY OBJECTIVES:

I. To characterize the patient-reported cosmetic appearance of the breast over time, as assessed by GCS.

II. To determine short- and long-term physician-reported cosmetic appearance of the breast, as assessed by GCS.

III. To evaluate the acute and late patient-reported radiation-associated toxicities.

IV. To evaluate the acute and late physician-reported radiation-associated toxicities.

V. To estimate:

Va. 5-year in-breast recurrence; Vb. 5-year distant recurrence; Vc. 5-year disease-free survival (DFS); Vd. 5-year overall survival (OS).

EXPLORATORY OBJECTIVES:

I. To evaluate patient-reported quality-of-life (QoL). II. To evaluate volumetric and dosimetric factors associated with acceptable breast cosmesis.

III. To evaluate volumetric and dosimetric factors associated with acute and late radiation-associated toxicities.

OUTLINE:

Patients undergo UF-WBI with CB once daily (QD) on consecutive business days for up to 5 fractions in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo cone-beam computed tomography (CBCT) prior to each radiation treatment.

After completion of study treatment, patients are followed up at 1 month, 6 months, then annually for up to 5 years.

03

Conditions studied

  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • Breast Carcinoma

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of the participant and/or legally authorized representative
  • Age: ≥ 40 years
  • Female
  • Ability to read and understand English for questionnaires
  • confirmed breast cancer
  • must be epithelial. Non-epithelial breast malignancies such as lymphoma or sarcoma are not allowed
  • Patients must have undergone breast conserving surgery. Re-excision for negative margins is allowed
  • Patients must have undergone surgical staging of the axilla (sentinel lymph node or axillary lymph node dissection)
  • Must have at least one-high risk feature that would necessitate a lumpectomy cavity boost by the treating radiation oncologist
  • Patient must have physician-reported "Excellent" or "Good" cosmesis post-lumpectomy and prior to radiation therapy based on the 4-point Global Cosmetic Score
  • Women of (WOCBP): negative urine or serum pregnancy test

    • If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
    • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Exclusion criteria

Exclusion Criteria:

  • Prior radiation to the region of the involved breast that in the opinion of the investigator would preclude breast irradiation
  • Pathologically or clinically involved regional lymph nodes necessitating comprehensive regional nodal irradiation that includes the supraclavicular fossa
  • uncontrolled illness
  • Stage IV breast cancer
  • Diagnosis of Paget's disease of the nipple
  • Other prior or active . Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial
  • Pregnant or breastfeeding
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    Treatment (UF-WBI with CB)

    Patients undergo UF-WBI with CB QD on consecutive business days for up to 5 fractions in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CBCT prior to each radiation treatment.

    Procedure: Cone-Beam Computed Tomography · Radiation: Hypofractionated External Beam Radiation Therapy · Other: Questionnaire Administration · Radiation: Radiation Boost · Radiation: Whole Breast Irradiation

Interventions

  • ProcedureCone-Beam Computed Tomography

    Undergo CBCT

    Also known as: Cone Beam Computed Tomography, Cone Beam CT

  • RadiationHypofractionated External Beam Radiation Therapy

    Undergo UF-WBI with CB

  • OtherQuestionnaire Administration

    Ancillary studies

  • RadiationRadiation Boost

    Undergo UF-WBI with CB

    Also known as: BOOST, Boost Radiation, Boost Radiation Therapy, Boost Radiotherapy, Radiation Therapy Boost, Radiotherapy Boost

  • RadiationWhole Breast Irradiation

    Undergo UF-WBI with CB

06

What researchers measure

Primary outcomes

  1. Response rate

    Responding patients are defined as patients with a rating of either "excellent" or "good" on the 4-point Global Cosmesis Score (GCS). Will be estimated along with the 95% exact binomial confidence interval.

    Time frame: At 1 year

Secondary outcomes

  1. Patient-reported cosmetic outcome using GCS - Baseline

    For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided.

    Time frame: At baseline

  2. Patient-reported cosmetic outcome using GCS - 6 months

    For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided.

    Time frame: At 6 months

  3. Patient-reported cosmetic outcome using GCS - 1 year

    For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided.

    Time frame: At 1 year

  4. Patient-reported cosmetic outcome using GCS - 2 years

    For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided.

    Time frame: At 2 years

  5. Patient-reported cosmetic outcome using GCS - 3 years

    For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided.

    Time frame: At 3 years

  6. Physician-reported cosmetic outcome using GCS

    For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided. For categorical variables, counts and percentages will be provided.

    Time frame: At baseline, at 6 months and at years 1, 2, and 3

  7. Patient-reported radiation-associated toxicities

    Will be assessed and graded using Patient-Reported Outcome Common Terminology Criteria for Adverse Events. Observed toxicities will be summarized by type, severity, and attribution. For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided. For categorical variables, counts and percentages will be provided.

    Time frame: At 1 month, 6 months, and 1 year

  8. Physician-reported radiation-associated toxicities

    Will be assessed and graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Observed toxicities will be summarized by type, severity, and attribution. For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided. For categorical variables, counts and percentages will be provided.

    Time frame: At 1 month, 6 months, and years 1, 2, and 3

  9. Incidence of in-breast disease recurrence

    Will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided. For categorical variables, counts and percentages will be provided.

    Time frame: Up to 5 years

  10. Incidence of metastatic disease

    Will be evaluated using RECIST criteria. For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided. For categorical variables, counts and percentages will be provided.

    Time frame: Up to 5 years

  11. Disease free survival

    Will be estimated using the Kaplan-Meier method with Greenwood variance estimator and 95% confidence interval will be constructed based on log-log transformation.

    Time frame: From start of treatment to in-breast recurrence, metastatic disease, or death from any cause, whichever occurs first, assessed up to 5 years

  12. Overall survival

    Will be estimated using the Kaplan-Meier method with Greenwood variance estimator and 95% confidence interval will be constructed based on log-log transformation.

    Time frame: From start of treatment to death from any cause, assessed up to 5 years

07

Study locations

6 of 7 sites recruiting
  • City of Hope at Arcadia
    Arcadia, California 91007, United States
    Recruiting
    • Stephanie M. Yoon · Contactstyoon@coh.org · 626-873-5241
    • Stephanie M. Yoon · Principal investigator
  • City of Hope Medical Center
    Duarte, California 91010, United States
    Recruiting
    • Stephanie M. Yoon · Contactstyoon@coh.org · 626-873-5241
    • Stephanie M. Yoon · Principal investigator
  • City of Hope at Irvine Lennar
    Irvine, California 92618, United States
    Not yet recruiting
    • Stephanie M. Yoon · Contactstyoon@coh.org · 626-873-5241
    • Stephanie M. Yoon · Principal investigator
  • City of Hope Antelope Valley
    Lancaster, California 93534, United States
    Recruiting
    • Stephanie M. Yoon · Contactstyoon@coh.org · 626-873-5241
    • Stephanie M. Yoon · Principal investigator
  • City of Hope South Pasadena
    South Pasadena, California 91030, United States
    Recruiting
    • Stephanie M. Yoon · Contactstyoon@coh.org · 626-873-5241
    • Stephanie M. Yoon · Principal investigator
  • City of Hope at South Bay
    Torrance, California 90503, United States
    Recruiting
  • City of Hope Upland
    Upland, California 91786, United States
    Recruiting
    • Stephanie M. Yoon · Contactstyoon@coh.org · 626-873-5241
    • Stephanie M. Yoon · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jan 2028, 29 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 29 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2025
First posted
May 2, 2025
StartActual
Aug 28, 2025
Primary completionEst.
Jan 31, 2028
CompletionEst.
Jan 31, 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06954831
Responsible party
Sponsor
First posted
May 2, 2025
Start date
Aug 28, 2025
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Stephanie M Yoon
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion